Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Combinations
- Registration Number
- NCT05414461
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Brief Summary
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 97
Inclusion Criteria
- patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment
- patients with identified genomic status
Exclusion Criteria
- patients who received immune monotherapy
- patients who stopped treatment for any reason without identified response assessment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Combination treatment Combinations PD-1 inhibitor-based combination treatment
- Primary Outcome Measures
Name Time Method Durable clinical benefit immediately after the intervention Rate of patients who acheived CR or PR or SD that lasted more than 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The First Affiliated Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China